Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Skinvisible has signed an exclusive licensing agreement with Embil Pharmaceutical, for the right to develop and market two of Skinvisible's prescription anti-acne products formulated with Invisicare and the active ingredients clindamycin HCL, and retinoic acid.
Subscribe to our email newsletter
This agreement with Embil, a multi-national dermatology company based in Turkey, is the company’s second entry into the $2.8 billion acne market. The territory includes Turkey, Azerbaijan, Kazakhstan, Kyrgyzstan, Turkmenistan, and Uzbekistan, as well as the South East Asian countries of Indonesia, Malaysia, and the Philippines where Embil will seek marketing approval.
This agreement, brought to the company by Riley-Nacht, one of the company’s marketing partners, gives Embil the right to manufacture, distribute and market these acne formulations in a dual chamber device in the territory specified above. Skinvisible will receive a development fee, a license fee allocated in milestone payments as well as royalties based on product sales.
Skinvisible is also seeking to license the company’s portfolio of over 25 topical dermatology products formulated with Invisicare including prescription and over-the-counter products for the treatment of atopic dermatitis, fungal infections, anti-inflammatories, as well as hand sanitizers, anti-aging, analgesic and sunscreen products.